摘要
【摘要】目的：探究应用替诺福韦治疗代偿期乙肝肝硬化的有效性及血清甲状腺激素的水平。方法：选取 2018年 3月一 2020年 2月在我院接受治疗的 7 2例代偿期乙肝肝硬化患者随机分为两组，对照组口服恩替卡韦治疗，观察组空腹服用替诺福韦，观察两组患者的肝功能改善情况、 HBV-DNA转阴率及治疗前后观察组血清甲状腺激素水平变化。结果：治疗后观察组患者的肝功能评分 AST（ 39.03±9.62） U/L、 ALT（ 38.89±9.16） U/L、 Child-Pugh（ 3.21±0.94）分均明显优于对照组，具有统计学意义（ P<0.05） ;观察组患者的 HBV-DNA转阴率（ 94.44%）与对照组 HBV-DNA转阴率（ 88.89%）无统计学意义（ P>0.05） ;治疗后观察组患者血清甲状腺激素水平均好转， HBV-DNA转阴者改善更为明显，有统计学意义（ P<0.05）。结论：应用替诺福韦治疗代偿期乙肝肝硬化的有效性良好，推荐临床推广应用。
【关键词】替诺福韦 ;恩替卡韦 ;代偿期乙肝肝硬化 ;有效性 ;血清甲状腺激素水平 ;评估
[Abstract] Objective: To explore the efficacy of tenofovir in the treatment of compensatory hepatitis B cirrhosis and the level of serum thyroid hormone. Methods: from March 2018 to February 2020, 72 patients with compensatory hepatitis B cirrhosis were randomly divided into two groups. The control group was treated with entecavir orally, and the observation group was treated with tenofovir on an empty stomach. The improvement of liver function, the negative rate of HBV-DNA and the change of serum thyroid hormone level before and after treatment were observed. Results: the scores of AST (39.03 ± 9.62) U / L, ALT (38.89 ± 9.16) U / L and child Pugh (3.21 ± 0.94) in the observation group were significantly higher than those in the control group (P < 0.05), and the negative rate of HBV-DNA in the observation group (94.44%) was not significantly higher than that in the control group (88.89%); After treatment, the level of serum thyroid hormone in the observation group was improved, especially in the HBV-DNA negative group (P < 0.05). Conclusion: tenofovir is effective in the treatment of compensatory hepatitis B cirrhosis, which is recommended for clinical application.
出版日期
2020年08月18日（中国期刊网平台首次上网日期，不代表论文的发表时间）
